PARP1 and neoplasm: Previous studies of combinations of PARP inhibitors with PD-(L)1 inhibitors have demonstrated antitumour activity in a variety of tumour types, including in patients with TNBC with BRCAmut, although there are limited data from head-to-head clinical trials of the combinations versus their component monotherapies [3, 10, 24, 43–45].